Hereditary transthyretin amyloidosis (ATTRv, also called hATTR) is caused by a disease-causing TTR variant that can lead to amyloid deposits in tissues. The diagnosis brings together three questions: Is amyloid causing the person’s symptoms? Which protein forms the deposits? Is the condition inherited? A heart scan, a biopsy and a genetic test address different parts of that investigation.
Keeping those questions separate prevents an important mistake: treating all amyloidosis as the same disease. This guide explains the diagnostic sequence, including why a negative TTR test does not rule out all amyloidosis. The practical examples are fictional.
ATTRv, ATTRwt and AL: similar findings, different causes
| Type | Protein involved | Genetic meaning |
|---|---|---|
| Hereditary ATTR (ATTRv) | Transthyretin | A disease-causing TTR variant is present; relatives may be at risk. |
| Wild-type ATTR (ATTRwt) | Transthyretin without a disease-causing TTR sequence variant | This form is not explained by an inherited pathogenic TTR variant. |
| AL amyloidosis | Immunoglobulin light chains produced by a clonal cell population | TTR sequencing does not diagnose or exclude it. |
ATTRv can affect peripheral nerves, autonomic functions and the heart, with variable combinations. Symptoms may include numbness, weakness, dizziness on standing, bowel disturbance or cardiac symptoms. Such findings have many other causes. MedlinePlus Genetics explains the range of manifestations and autosomal dominant inheritance.
Step 1: investigate the organ findings and check for AL
When cardiac amyloidosis is suspected, echocardiography or cardiac MRI can help identify a suggestive pattern; these findings alone do not establish the amyloid protein. The 2025 ACC guidance places exclusion of AL early in the evaluation. The monoclonal protein assessment combines serum free light chains, serum immunofixation and urine immunofixation. Routine protein electrophoresis without immunofixation is not an equivalent substitute.
An abnormal screen needs expert interpretation, including kidney function and the particular laboratory assay. It does not by itself prove that a monoclonal protein is forming tissue deposits. Nevertheless, possible AL deserves prompt specialist assessment because its evaluation and treatment differ from ATTR.
Step 2: understand when a bone-tracer scan can avoid biopsy
Appropriate technetium-labelled bone-tracer scintigraphy can establish cardiac ATTR without biopsy in a defined setting: a compatible clinical assessment, sufficiently strong myocardial uptake, and no evidence of a monoclonal protein on the required tests. Gillmore and colleagues’ primary diagnostic study established the importance of combining scan findings with monoclonal protein testing, rather than interpreting the scan in isolation.
The imaging protocol matters. SPECT helps distinguish uptake in the heart muscle from activity in the blood pool or overlapping structures. The multisociety imaging recommendations describe acquisition and interpretation. An equivocal or negative scan does not settle every form or stage of amyloidosis; persistent clinical suspicion requires further assessment.
Example: a positive scan and a monoclonal protein. Helen is told that her scan “looks like ATTR,” but serum testing also identifies a monoclonal protein. She cannot simply apply the nonbiopsy rule. AL, ATTR with an incidental monoclonal gammopathy, or another explanation must be distinguished. A specialist may recommend tissue sampling and reliable amyloid typing. Neither result should be ignored to make the story simpler.
Step 3: if tissue is sampled, identify the protein
Finding amyloid in a biopsy establishes a deposit, but the protein still needs typing by an appropriate validated method. A negative sample from one site does not necessarily exclude deposits elsewhere. The ACC diagnostic consensus summary specifically cautions that a negative fat-pad biopsy does not exclude AL or ATTR. The choice of further sampling depends on the organ findings and the balance of diagnostic benefit and risk.
Example: a reassuring test with the wrong scope. Martin has progressive neuropathy and cardiac abnormalities. His fat-pad sample is negative. The useful question is whether the overall evaluation now explains his symptoms—not whether one negative specimen can cancel the rest of the evidence. His specialist can decide whether another site or method is warranted.
Step 4: use TTR testing to distinguish hereditary and wild-type disease
Once ATTR is established, genetic counselling and TTR testing help determine whether it is hereditary. Older age and an apparently negative family history do not reliably establish wild-type ATTR. Relatives may have been undiagnosed, may develop disease later, or may carry a variant without manifestations. The GeneReviews chapter on hereditary transthyretin amyloidosis describes genetic diagnosis, counselling and surveillance.
Example: the negative gene test. An older adult has a specialist-confirmed cardiac ATTR diagnosis but no pathogenic TTR variant identified. That finding can support ATTRwt in the appropriate work-up. It does not mean the amyloid diagnosis has disappeared. Conversely, a negative TTR result obtained before amyloid typing cannot rule out AL.
A variant of uncertain significance should not be treated as proof of hereditary ATTR. Record the exact transcript and variant description and seek interpretation in the clinical context. The variant classification guide explains why uncertainty is different from a positive diagnosis. For the name T60A, see TTR Thr80Ala and legacy variant numbering.
What a confirmed result means for relatives
For a parent with one pathogenic TTR variant, each child usually has a 50% chance of inheriting that variant. That is a transmission probability, not a prediction that symptoms will occur at a particular age or with the same severity. A symptom-free adult relative who tests positive needs an individualized surveillance discussion; the result alone does not demonstrate present organ involvement. Our penetrance guide explains this difference.
Bring these five questions to the appointment
- What evidence establishes amyloidosis, and which organs are involved?
- Have all three monoclonal protein tests been completed and interpreted?
- Does the scan meet the complete nonbiopsy pathway, or is tissue typing needed?
- What exactly does the TTR result establish—and what does it leave unresolved?
- Who coordinates cardiac, neurological, genetic and family follow-up?
Use the care finder to prepare a referral discussion and the variant worksheet to record the genetic result without personal identifiers. For population questions, see our separate guide to hereditary ATTR prevalence in the UK; a population estimate is not an individual’s risk estimate.